KR20180077484A - Compositions for Preventing or Treating Glaucoma or Macular Degeneration Comprising Water Soluble Extraction of Rosa hybrida or Fractions thereof - Google Patents
Compositions for Preventing or Treating Glaucoma or Macular Degeneration Comprising Water Soluble Extraction of Rosa hybrida or Fractions thereof Download PDFInfo
- Publication number
- KR20180077484A KR20180077484A KR1020160181882A KR20160181882A KR20180077484A KR 20180077484 A KR20180077484 A KR 20180077484A KR 1020160181882 A KR1020160181882 A KR 1020160181882A KR 20160181882 A KR20160181882 A KR 20160181882A KR 20180077484 A KR20180077484 A KR 20180077484A
- Authority
- KR
- South Korea
- Prior art keywords
- macular degeneration
- preventing
- composition
- glaucoma
- fraction
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 28
- 208000002780 macular degeneration Diseases 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 235000002315 Rosa hybrid cultivar Nutrition 0.000 title claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract description 9
- 238000000605 extraction Methods 0.000 title abstract 7
- 244000037691 Rosa hybrida Species 0.000 title abstract 4
- 230000034994 death Effects 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 24
- 210000001328 optic nerve Anatomy 0.000 claims description 22
- 241000220317 Rosa Species 0.000 claims description 20
- 244000154511 Rosa hybrid cultivar Species 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000006286 aqueous extract Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 235000004789 Rosa xanthina Nutrition 0.000 description 5
- 241000109329 Rosa xanthina Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- -1 etc.) Substances 0.000 description 4
- 230000004410 intraocular pressure Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000003994 retinal ganglion cell Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047555 Visual field defect Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- Y10S514/912—
-
- Y10S514/913—
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 장미의 수용성 추출물 또는 이의 분획물을 포함하는 녹내장 또는 황반변성 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for preventing or treating glaucoma or macular degeneration comprising a water-soluble extract of roses or a fraction thereof.
녹내장이란 안방수(眼房水)의 순환 장해에 의해 안방수가 축적되고, 지속적으로 안압이 상승하여 시신경이 압박됨으로써, 일시적 또는 영구적인 시야 결손, 시력 저하를 일으키는 시기능 장해를 특징으로 한다고 알려져 있는 안질환으로, 일반적인 발병 원인은 안압 상승으로 알려져 있지만, 이밖에 안압이 정상치여도 시신경에 장해가 나타나는 저안압 녹내장, 안압이 높아도 시신경 장애가 나타나지 않는 고안압증도 알려져 있다. It is known that glaucoma is characterized by the accumulation of mental defenses by the circulatory disorder of the ocular atresia, persistent elevation of the intraocular pressure and compression of the optic nerve, resulting in temporal or permanent visual field defects and visual disturbances It is known that the cause of ophthalmic ophthalmologic disease is the elevation of intraocular pressure. However, it is known that hypotonic glaucoma in which the optic nerve is obstructed even when the intraocular pressure is normal, and ocular hypertension in which the optic nerve obstruction does not occur even when the intraocular pressure is high.
특히, Mohammadali Almasieh 등에 따르면, 모든 형태의 녹내장의 병리생리학에서 망막절 세포(Retinal ganglion cells, RGCs)와 같은 시신경 세포의 사멸이 일어나며, 상기 RGC의 사멸을 야기하는 축삭돌기 손상이 활성산소 슈퍼옥사이드에 의해 촉진되는 바(The molecular basis of retinal ganglion cell death in glaucoma; Mohammadali Almasieh et al., Progress in Retinal and Eye Research 31(2012) 152-181), 상기 시신경 세포들에서 산화 스트레스를 방지하여 사멸을 억제하는 물질은 녹내장의 발병 및 진행을 억제할 수 있는 치료제로서 활용될 수 있다.In particular, according to Mohammadali Almasieh et al., Pathological physiology of all types of glaucoma results in the death of optic nerve cells such as retinal ganglion cells (RGCs), and the axon damage causing the RGC death is induced in the active oxygen superoxide (Molecular basis of retinal ganglion cell death in glaucoma, Mohammadali Almasieh et al., Progress in Retinal and Eye Research 31 (2012) 152-181), inhibit oxidative stress in the optic nerve cells and inhibit death Can be utilized as a therapeutic agent capable of inhibiting the onset and progression of glaucoma.
현재 녹내장의 치료에는, 약물치료, 레이저 치료, 수술 치료를 수행하고 있으며, 약물 치료로 부작용을 회피하는 국소 투여인 점안제가 주로 사용되고 있고, 임상에서 사용되고 있는 녹내장 치료약에는 교감신경 작동약(α2 아고니스트, 비선택적 아드레날린 작동약 등), 부교감신경 작동약, 교감신경 억제약(α1 블로커, β 블로커, α1β 블로커 등), 탄산탈수효소 저해약, 고장(高張) 침투압약 등이 있지만, 최근 안압 강하 작용이 강하고 부작용이 비교적 적은 프로스타글란딘계 약제가 제1선택약으로 부상하고 있다. 그러나 아직까지 근본적으로 시신경 세포의 사멸을 억제하는 치료약은 개발되지 않았다.In the treatment of current glaucoma, and to perform the medical treatment, laser therapy, surgical therapy, the topical administration of eye drops to avoid the side effects as a drug treatment is mainly used, and glaucoma therapeutic agent being used in clinical include sympathetic agonists (α 2 agonist ( 1 blockers, beta blockers, alpha 1 beta blockers, etc.), carbonic anhydrase inhibitors, hypertension, and osmotic pressure drugs. A prostaglandin agent with strong intraocular pressure lowering effect and relatively low side effects is emerging as the first choice. However, to date, no therapeutic drug has been developed to inhibit the death of optic nerve cells.
또한, 황반변성은 망막 상피 세포, 망막 및 맥락막 모세혈관층의 점진적인 변성으로 인해 고령자들에게 시력상실을 가져오는 질환으로 알려져 있다. 초기 단계의 황반변성은 브르크막(Bruch's membrane)과 망막상피세포 사이에 드루겐(drusen)이라 불리는 세포 외 침착이 형성된 비정상적인 망막상피세포가 관찰되는 것이 특징이다. 후기 단계의 황반변성은 크게 삼출성 황반변성(습성 황반변성)과 위축성 황반변성(건성 황반변성)으로 나뉘며, 산화 스트레스 및 염증이 황반변성의 병인으로 알려져 있으나 아직까지 정확한 메커니즘은 규명된 바가 없다.Macular degeneration is also known to cause vision loss in elderly people due to gradual degeneration of the retinal epithelium, retina and choroidal capillary layers. Early stage of AMD is characterized by the presence of abnormal retinal epithelial cells with extracellular deposition called drusen between Bruch's membrane and retinal epithelial cells. Macular degeneration in late stages is divided into exudative macular degeneration (AMD) and atrophic macular degeneration (AMD). Oxidative stress and inflammation are known to be a pathogenesis of AMD. However, the precise mechanism has not yet been elucidated.
한편, 식물은 의약품 개발에서 매우 유용한 자원으로서 제공되어 왔으며, 많은 나라의 연구자에 의해 건강에 유효한 식물을 동정하는 연구가 계속 진행되고 있다. 식물은 매우 다양한 범위의 이차 대사산물로 알려진 저분자량 천연 물질, 예를 들어, 아스코르브산, 글루타치온, 요산, 토코페롤, 카로티노이드, 폴리페놀 등을 생산할 수 있고, 이 화합물들은 특히 식물에서 다양한 기능을 수행한다.On the other hand, plants have been provided as very useful resources in the development of medicines, and studies are underway to identify plants that are valid for health by researchers in many countries. Plants can produce low molecular weight natural substances, such as ascorbic acid, glutathione, uric acid, tocopherol, carotenoids, polyphenols and the like, which are known as a wide variety of secondary metabolites, .
장미(Rosa hybrida)는 향수산업에서 방향성 오일을 제공하는 원천으로 사용되어 왔으며, 최근 당뇨, 통증 및 염증성 질환을 치료하기 위한 약물 후보로도 거론되고 있다(Cho et al., 2003, Phytomedicine 10, 544-551; Ng et al., (2005) Biochem. Cell Biol. 83, 78-85). 그러나 아직까지 장미를 물로 추출한 추출물의 시신경 세포 보호 효과에 대해서는 보고된 바가 없다.Rose (Rosa hybrida) has been used as a source of aromatic oil in the perfume industry and has recently been proposed as a drug candidate for the treatment of diabetes, pain and inflammatory diseases (Cho et al., 2003, Phytomedicine 10, 544 Ng et al., (2005) Biochem. Cell Biol. 83, 78-85). However, there has been no report on the effect of extracts of rose extracts on optic nerve cells.
본 발명의 목적은 산화 스트레스로부터 시신경 세포를 보호하여 녹내장 또는 황반변성을 예방 또는 치료할 수 있는 약학 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition capable of preventing or treating glaucoma or macular degeneration by protecting optic nerve cells from oxidative stress.
본 발명의 다른 목적은 산화 스트레스로부터 시신경 세포를 보호하여 녹내장 또는 황반변성을 예방 또는 개선할 수 있는 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition capable of preventing or improving glaucoma or macular degeneration by protecting optic nerve cells from oxidative stress.
상기 목적을 달성하기 위하여 본 발명은, 장미(Rosa hybrida)의 수용성 추출물 또는 이의 분획물을 유효성분으로 포함하는 녹내장 또는 황반변성 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating glaucoma or macular degeneration comprising an aqueous extract of Rosa hybrida or a fraction thereof as an active ingredient.
상기 다른 목적을 달성하기 위하여 본 발명은, 장미(Rosa hybrida)의 수용성 추출물 또는 이의 분획물을 유효성분으로 포함하는 녹내장 또는 황반변성 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention provides a health functional food composition for preventing or ameliorating glaucoma or macular degeneration comprising an aqueous extract of Rosa hybrida or a fraction thereof as an active ingredient.
본 발명에 따르면, 장미(Rosa hybrida)를 물로 추출한 추출물 또는 이의 분획물이 산화 스트레스 하에서 시신경 세포의 사멸을 억제하여 생존율을 증가시킬 수 있는 바, 이를 포함하는 조성물은 시신경 세포의 사멸로 유발되는 녹내장 또는 황반변성을 효과적으로 치료할 수 있다.According to the present invention, the extract of Rose (Rosa hybrida) extracted with water or a fraction thereof can inhibit the death of optic nerve cells under oxidative stress and increase the survival rate. The composition comprising the same can be used for the treatment of glaucoma Macular degeneration can be effectively treated.
도 1은 본 발명의 하나의 실시예에 따른 장미 수용성 추출물이 과산화수소로부터 시신경 세포를 보호하는 효과를 확인한 결과이다.FIG. 1 shows the results of confirming the effect of protecting the optic nerve cells from hydrogen peroxide by the water-soluble extract of roses according to one embodiment of the present invention.
이하, 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 장미(Rosa hybrida)의 수용성 추출물 또는 이의 분획물을 유효성분으로 포함하는 녹내장 또는 황반변성 예방 또는 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating glaucoma or macular degeneration comprising an aqueous extract of Rosa hybrida or a fraction thereof as an active ingredient.
본 발명의 일 실시예에서, 상기 장미의 수용성 추출물이 과산화수소 처리 환경에서 시신경 세포의 사멸을 억제하는 효과를 확인한 바, 상기 장미의 수용성 추출물 또는 이의 분획물을 포함하는 조성물은 항산화 효과를 나타냄으로써 시신경 세포가 죽는 증상이 나타나는 녹내장 또는 황반변성을 효과적으로 예방 또는 치료할 수 있다.In one embodiment of the present invention, the water-soluble extract of the rose showed an effect of inhibiting the death of optic nerve cells in a hydrogen peroxide treatment environment. The composition containing the water-soluble extract of the rose or a fraction thereof showed an antioxidative effect, Can be effectively prevented or treated.
이때, 상기 장미의 수용성 추출물 또는 이의 분획물은 항산화 효과를 나타내어 시신경 세포의 사멸을 방지할 수 있는 바, 이러한 기작으로 녹내장 또는 황반변성을 예방 또는 치료할 수 있다.At this time, the water-soluble extract of the rose or its fraction has an antioxidative effect and can prevent the death of the optic nerve cell. Such a mechanism can prevent or treat glaucoma or macular degeneration.
상기 장미의 수용성 추출물 또는 이의 분획물은 전체 조성물 100 중량부에 대하여 0.01 내지 50 중량부로 포함될 수 있는 바, 상기 범위로 장미의 수용성 추출물 또는 이의 분획물이 포함될 때 시신경 세포를 산화 스트레스로부터 가장 효과적으로 보호하여 최적의 녹내장 또는 황반변성 치료 효과를 나타낼 수 있으므로 바람직하다.The water-soluble extract of the rose or its fraction may be contained in an amount of 0.01 to 50 parts by weight based on 100 parts by weight of the total composition. When the water-soluble extract of the rose or the fraction thereof is contained in the range, the optic nerve cell is most effectively protected from oxidative stress Of glaucoma or macular degeneration.
본 발명에서 사용되는 용어 "예방"은, 상기 장미의 수용성 추출물 또는 이의 분획물을 함유하는 조성물의 투여로 녹내장 또는 황반변성을 억제 또는 지연시키는 모든 행위를 의미한다. 또한, 본 발명에서 사용되는 용어 "치료"는, 상기 장미의 수용성 추출물 또는 이의 분획물을 함유하는 조성물의 투여로 녹내장 또는 황반변성의 증세가 호전되거나 완치되는 모든 행위를 의미한다.As used herein, the term "prevention " means any action that inhibits or delays glaucoma or macular degeneration by administration of a composition containing a water-soluble extract of the rose or a fraction thereof. The term "treatment ", as used herein, refers to any action in which the symptom of glaucoma or macular degeneration is ameliorated or cured by administration of a composition containing a water-soluble extract of the rose or a fraction thereof.
본 발명의 약학 조성물은 투여를 위하여, 상기 기재한 유효성분 이외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 포함할 수 있다. 상기 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.The pharmaceutical composition of the present invention may contain, for administration, a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-mentioned effective ingredient. Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용할 수 있다. 상세하게는 제형화할 경우 통상 사용하는 충진제, 중량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형 제제로는 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하나, 이에 한정되는 것은 아니다. 이러한 고형 제제는 상기 장미의 수용성 추출물 또는 이의 분획물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘 카보네이트, 수크로오스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등을 첨가하여 조제될 수 있다. 비경구 투여를 위한 제제는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조 제제 및 과제를 포함한다. 비수성 용제 및 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 오일, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로솔, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols or the like, oral preparations, suppositories or sterilized injection solutions according to conventional methods . In detail, when formulating, it can be prepared using diluents or excipients such as fillers, weights, binders, humectants, disintegrants, surfactants and the like which are usually used. Solid form preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules and the like. Such a solid preparation can be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. in the aqueous extract or fraction thereof of the rose. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration, liquid paraffin, and various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and tasks. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. As a base for suppositories, it is possible to use witepsol, macrosole, tween 61, cacao paper, laurin, glycerogelatin and the like.
본 발명의 약학 조성물의 적합한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있는 바, 상기 장미의 수용성 추출물 또는 이의 분획물의 일일 투여량은 바람직하게는 0.01 mg/kg 내지 500 mg/kg이며, 필요에 따라 일일 1회 내지 수회로 나누어 투여할 수 있다.A suitable dose of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, and the time, but can be appropriately selected by those skilled in the art. The dose is preferably 0.01 mg / kg to 500 mg / kg, and may be administered once to several times per day as needed.
더욱이, 본 발명은 장미(Rosa hybrida)의 수용성 추출물 또는 이의 분획물을 유효성분으로 포함하는 녹내장 또는 황반변성 예방 또는 개선용 건강기능식품 조성물을 제공한다.Furthermore, the present invention provides a health functional food composition for preventing or ameliorating glaucoma or macular degeneration comprising an aqueous extract of Rosa hybrida or a fraction thereof as an active ingredient.
이때, 상기 장미의 수용성 추출물 또는 이의 분획물은 항산화 효과를 나타내어 시신경 세포의 사멸을 방지할 수 있는 바, 이러한 기작을 통해 녹내장 또는 황반변성을 예방 또는 개선할 수 있다At this time, the water-soluble extract of the rose or its fractions exhibits an antioxidative effect and can prevent the death of optic nerve cells. Thus, glaucoma or macular degeneration can be prevented or improved through such a mechanism
상기 건강기능식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스, 합성 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 또한, 건강기능식품 조성물은 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알코올 및 비타민 복합제 중 어느 하나의 형태일 수 있다.The health functional food composition may contain various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts , Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, synthetic fruit juices and vegetable drinks. These components may be used independently or in combination. The health functional food composition may be in the form of any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcohol and vitamin complex Lt; / RTI >
또한, 상기 건강기능식품 조성물은 식품첨가물을 추가로 포함할 수 있으며, "식품첨가물"로서의 적합 여부는 다른 규정이 없는 한 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반 시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.In addition, the health functional food composition may further include a food additive, and the suitability of the food functional additive as a "food additive " is not limited by the general rules and general test methods approved by the Food and Drug Administration It shall be judged according to standards and standards for items.
상기 "식품첨가물공전"에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산 칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀룰로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류 첨가 알칼리제, 보존 료제제, 타르색소 제제 등의 혼합 제제류 등을 들 수 있다.Examples of the products that have been used in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, sensory coloring matter, licorice extract, crystalline cellulose, high- - Mixed preparations such as a sodium glutamate preparation, a noodle-added alkaline agent, a preservative preparation, and a tar coloring agent.
이때, 건강기능식품 조성물을 제조하는 과정에서 식품에 첨가되는 본 발명에 따른 장미의 수용성 추출물 또는 이의 분획물은 필요에 따라 그 함량을 적절히 가감할 수 있다.At this time, the water-soluble extract of the rose or the fraction thereof according to the present invention, which is added to the food during the production of the health functional food composition, can be appropriately increased or decreased as needed.
이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이며 본 발명의 내용을 예시하는 것일 뿐이므로 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail with reference to the following examples. It is to be understood that both the foregoing description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. no.
<준비예 1> 장미 추출물 및 세포의 준비<Preparation Example 1> Preparation of roses extract and cells
장미 수용성 추출물의 시신경 세포 보호 효과를 확인하기에 앞서, 실험에 필요한 장미(rosa hybrida)를 허브나라농원에서 제공받았다. 이후, 수용성 추출물을 85℃ 물로 30분 동안 2회 추출한 후 증발기로 농축하여 획득하였다. 시신경 세포인 R28 세포는 아주대병원 안과학교실 안재홍 교수님에게 분양받은 후, 실험 때까지 저포도당(low glucose), 10% FBS, 1% 페니실린 및 스트렙토마이신이 들어있는 DMEM배지에 37℃, 5% CO2의 조건에서 배양하였다.Prior to confirming the optic nerve cell protection effect of rose water-soluble extracts, rose ( rosa hybrida ) required for the experiment was provided at the Hub Country Plant. Then, the water-soluble extract was extracted twice with water at 85 ° C for 30 minutes, and then concentrated with an evaporator. Optic nerve cell of R28 cells Ajou hospital after pre-sale to Ophthalmology Jae Hong Ahn Professor, low glucose (low glucose) until the experiment, 10% FBS, 1% penicillin and 37 ℃ in DMEM medium containing streptomycin, 5% CO 2 Lt; / RTI >
<< 실시예Example 1> 과산화수소 조건에서 장미 수용성 추출물의 시신경 보호 효과 1> Protective Effect of Rose Water-Soluble Extract on Optic Nerve Condition under Hydrogen Peroxide Conditions
상기 준비예 1에서 준비한 R28 세포에 장미 수용성 추출물을 농도별로 3 ㎍/ml, 10 ㎍/ml, 30 ㎍/ml 및 100 ㎍/ml 씩 30분간 전처리하였다. 이후, 0.5 mM의 과산화수소(H2O2)를 24시간 처리하여 독성을 야기한 후에 세포 생존율을 측정하였다. 구체적으로, 세포 생존율은 MTT 어세이를 통하여 MTT가 살아있는 세포의 미토콘드리아 환원효소(mitochondrial reductase)에 의해 포르마잔으로 형성되는 정도를 흡광도를 통해 측정함으로써 확인하였다. 음성 대조군(CTL)으로는 장미 수용성 추출물과 H2O2 모두 처리하지 않았다.R28 cells prepared in Preparation Example 1 were pretreated with 3 ug / ml, 10 ug / ml and 100 쨉 g / ml for 30 minutes for each concentration. Then, the cell viability was measured after 0.5 mM hydrogen peroxide (H 2 O 2 ) was treated for 24 hours to induce toxicity. Specifically, the cell viability was confirmed by measuring the extent of formation of formazan by mitochondrial reductase of living cells through MTT assay through absorbance. As a negative control (CTL), neither water soluble extract of rose nor H 2 O 2 was treated.
그 결과, 도 1에 나타난 바와 같이, 0.5 mM H2O2를 처리하여 시신경 세포의 세포 사멸을 유도한 환경에서, 장미 수용성 추출물이 농도 의존적으로 세포 사멸을 억제하는 것을 확인하였다(*P < 0.05 vs. CTL, #P < 0.05 vs. Veh). 특히, 장미 수용성 추출물을 100 ㎍/ml을 처리한 경우 거의 정상 수준(CTL)과 같은 세포 생존율을 회복하는 것을 확인할 수 있었다.As a result, as shown in Fig. 1, it was confirmed that the water-soluble extract of roses inhibited cell death in a concentration-dependent manner in an environment where 0.5 mM H 2 O 2 was treated to induce apoptosis cell apoptosis (* P <0.05 vs. CTL, # P < 0.05 vs. Veh. In particular, it was confirmed that the treatment of 100 ug / ml of the rose water-soluble extract restored the cell survival rate almost to the normal level (CTL).
따라서, 본 발명에 따른 장미의 수용성 추출물 또는 이의 분획물을 유효성분으로 포함하는 조성물은 산화 스트레스로부터 시신경 세포를 보호하여 시신경 세포의 사멸을 억제할 수 있으므로, 녹내장 또는 황반변성의 예방, 개선 또는 치료용 조성물로 활용될 수 있다.Therefore, the composition comprising the water-soluble extract of roses or the fractions thereof as an active ingredient according to the present invention can protect optic nerve cells from oxidative stress and inhibit the death of optic nerve cells. Therefore, the composition for prevention, improvement or treatment of glaucoma or macular degeneration .
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 즉, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다.While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will appreciate that such specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereby. Do. That is, the practical scope of the present invention is defined by the appended claims and their equivalents.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160181882A KR20180077484A (en) | 2016-12-29 | 2016-12-29 | Compositions for Preventing or Treating Glaucoma or Macular Degeneration Comprising Water Soluble Extraction of Rosa hybrida or Fractions thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160181882A KR20180077484A (en) | 2016-12-29 | 2016-12-29 | Compositions for Preventing or Treating Glaucoma or Macular Degeneration Comprising Water Soluble Extraction of Rosa hybrida or Fractions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180077484A true KR20180077484A (en) | 2018-07-09 |
Family
ID=62918943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160181882A KR20180077484A (en) | 2016-12-29 | 2016-12-29 | Compositions for Preventing or Treating Glaucoma or Macular Degeneration Comprising Water Soluble Extraction of Rosa hybrida or Fractions thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20180077484A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220162654A (en) * | 2022-11-10 | 2022-12-08 | 주식회사 아이두젠 | Composition for protecting eyesight or improving and preventing retinal diseases comprising extracts of stewartia pseudocamellia maxim |
-
2016
- 2016-12-29 KR KR1020160181882A patent/KR20180077484A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220162654A (en) * | 2022-11-10 | 2022-12-08 | 주식회사 아이두젠 | Composition for protecting eyesight or improving and preventing retinal diseases comprising extracts of stewartia pseudocamellia maxim |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101426356B1 (en) | Composition for preventing or treating retinal disease containing extracts of persimmon | |
| KR102120483B1 (en) | Pharmaceutical composition for preventing or treating of macular degeneration comprising Prunella vulgaris var. lilacina extract as an active ingredient | |
| US10610555B2 (en) | Method for alleviating osteoarthritis by using composite (HL-Joint 100) of achyranthes bidentata, eucommin ulmoides oliver and pomegranate extracts, which has antiinflammatory effect caused by COX2 and PGE2 inhibition, cartilage protective effect caused by MMP-2 and -9 inhibition and cartilage regeneration effect caused by increase in type II collagen synthesis | |
| KR101391308B1 (en) | Composition comprising the extracts and fractions of Gymnaster koraiensis for prevention or treatment of retinal diseases | |
| CN102821773B (en) | Composition for treating, preventing or relieving macular degeneration, containing vaccinium uliginosum extract or vaccinium uliginosum fractions as active ingredient | |
| KR101426307B1 (en) | Composition Comprising Extract of Daphne genkwa as Active Ingradient | |
| KR20180077484A (en) | Compositions for Preventing or Treating Glaucoma or Macular Degeneration Comprising Water Soluble Extraction of Rosa hybrida or Fractions thereof | |
| JP5893438B2 (en) | Retinopathy preventive or ameliorating agent | |
| KR20200042618A (en) | Composition for prevention or treatment of retinal diseases comprising extract of Centella asiatica | |
| KR20200059921A (en) | Composition for preventing or treating cancer comprising fruit extracts of alnus sibirica or fraction thereof | |
| KR102138251B1 (en) | A composition for preventing or treating cognitive dysfunction comprising Bauhinia extract | |
| KR20210075916A (en) | Pharmaceutical composition for the prevention or treatment of obesity or metabolic syndrome induced from obesity containing enteroccocus faecalis as an active ingredient | |
| KR101503792B1 (en) | Neuroprotective composition comprising extract or fractions of Vaccinium uliginosum as an active ingredient | |
| KR101894969B1 (en) | Pharmaceutical composition for preventing or treating hearing loss comprising an extract of peanut sprout | |
| KR20170073938A (en) | A composition for treating dry eye syndrome comprising a extract of Vaccinium Uliginosum as an active ingredient | |
| KR102138860B1 (en) | Composition for lowering intraocular pressure regulating comprising extract of maple leaves | |
| KR102683129B1 (en) | Composition for Protecting Eyesight or Preventing or Treating Retinal Diseases Comprising Extract of Humulus japonicus or Humulus scandens | |
| KR101941221B1 (en) | Composition for preventing, improving or treating macular degeneration comprising Phragmitis Rhizoma extract | |
| KR102612089B1 (en) | Composition for preventing and treating osteoporosis containing extract of Lindera obtusiloba leaf as an active ingredient | |
| KR101316088B1 (en) | Composition Comprising Extract of Rhodotypos scandens as Active Ingradient | |
| KR20130016679A (en) | Composition comprising extracts from leaves of cudrania tricuspidata for preventing or treating damage of nerve cells | |
| KR102115977B1 (en) | Composition for prevention or treatment of inflammatory eye disease comprising (7S,8R)-dihydrodehydrodiconiferylalcohol-9-β-D-glucopyranoside | |
| KR20240055549A (en) | Composition For Preventing Or Treating Eye Diseases Comprising Caragana sinica Extract | |
| KR101874594B1 (en) | A composition for prevention or treating cognitive dysfunction comprising Annona atemoya leaf extract or fraction thereof | |
| KR101404036B1 (en) | Extract of Crepidiastrum denticulatum for prevention or treatment of retinal diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |